Results 111 to 120 of about 4,245 (206)

Parapharyngeal space meningioma

Radiology Case Reports
Parapharyngeal space (PPS) meningiomas are rare extracranial tumors that can mimic more common PPS lesions. We report a case of a 23-year-old female who presented with a painless, progressive neck swelling and intraoral bulge.
Pranjal Rai, MD, Niyati Pokar, MBBS, Animesh Awadhiya, MBBS, Joe Joseph, MD, Dhairya A Lakhani, MD   +4 more
doaj   +1 more source

Peptide receptor radionuclide therapy with 90Y-DOTATOC in recurrent meningioma

, 2009
Purpose: Meningiomas are generally benign and in most cases surgery is curative. However, for high-grade histotypes or partially resected tumours, recurrence is fairly common.
Bodei, Lisa, AricÃ2, Demetrio, Cremonesi, Marta, Sansovini, Maddalena, Bartolomei, Mirco, Botteri, Edoardo, Baio, Silvia Melania, Paganelli, Giovanni, Grana, Chiara Maria, De Cicco, Concetta   +9 more
core   +1 more source

Success of 177Lu-DOTATATE therapy in a metastatic pituitary neuroendocrine tumor

Endocrine Oncology
Metastatic pituitary neuroendocrine tumors (PitNETs) are rare and often aggressive. Patients should be evaluated for metastatic disease when their biochemical presentation is discordant with pituitary tumor burden or when they present with non-pituitary,
Katherine I Wolf, Zhonglin Lu, Elizabeth A Hesseltine, Ka-Kit Wong, Francis P Worden, Tobias Else   +5 more
doaj   +1 more source

Case report: Resolution of VIPoma-related symptoms with peptide receptor radionuclide therapy

Frontiers in Oncology
Peptide receptor radionuclide therapy (PRRT) is used for the management of neuroendocrine tumors (NETs) not responsive to somatostatin analogs. In this case series, we report two patients with pancreatic vasoactive intestinal peptide (VIP)-secreting NETs
Turgut Bora Cengiz, Raksha Kulkarni, Virginia Corbett, Nasrin V. Ghesani, Edward Wolin, Munir V. Ghesani   +5 more
doaj   +1 more source

Correction: Peptide receptor radionuclide therapy (PRRT) in radioiodine-refractory thyroid cancer: A case report of significant response to lu177 DOTA-TATE treatment. [PDF]

Arch Endocrinol Metab, 2022
europepmc   +1 more source

The efficacy of ¹⁷⁷Lu-DOTATATE peptide receptor radionuclide therapy (PRRT) in patients with metastatic neuroendocrine tumours: a systematic review and meta-analysis. [PDF]

J Cancer Res Clin Oncol, 2020
Zhang J, Song Q, Cai L, Xie Y, Chen Y.
europepmc   +1 more source

Peptide receptor radionuclide therapy for ectopic Cushing’s syndrome caused by metastatic neuroendocrine neoplasms

Endocrine Oncology
Background: Metastatic gastroenteropancreatic neuroendocrine neoplasms (GEPNEN) can cause ectopic Cushing’s syndrome (ECS). ECS is highly morbid and medical therapy is complex and can be ineffective.
Emma Boehm, Terry Hung, Tim Akhurst, Ramin Alipour, Cherie Chiang, Rodney J Hicks, Michael S Hofman, Aravind S Ravi Kumar, Nirupa Sachithanandan, Javad Saghebi, Michael Michael, Grace Kong   +11 more
doaj   +1 more source

Preclinical and Clinical Studies of Peptide Receptor Radionuclide Therapy

, 2010
In the 1980s, the In-111-labeled somatostatin analog OctreoScan (Covidien, Hazelwood, MO) was developed for imaging of somatostatin receptor subtype 2 (sst(2)) overexpressing tumors.
van Eijck, Casper, Krenning, Eric, Koning, Gerben, Valkema, R., Jong, Marion, Pool, Stefan, Teunissen, Jaap, Kwekkeboom, Dik, Kam, BLR   +8 more
core   +1 more source

PReCedeNT trial: Phase III randomized-controlled trial of Lutetium - 177 DOTATATE Peptide Receptor Radionuclide Therapy (PRRT) plus Chemotherapy versus PRRT alone in FDG-avid, Well-differentiated Gastroenteropancreatic neuroendocrine tumors (GEP-NETs). [PDF]

BMC Cancer
Puranik AD, Dev ID, Yadav S, Rangarajan V, Agrawal A, Basu S, Chaudhari VA, Ramaswamy A, Ostwal V, Bhandare MS, Shrikhande SV, Parghane RV, Bhargava P, Bal MM, Yadav S, Patkar S, Goel M, Purandare NC, Shah S, Choudhury S, Ghosh S, Venkatachalam M.   +21 more
europepmc   +1 more source

Peptide Receptor Radionuclide Therapy (PRRT) Using Actinium-225- and Ac-225/Lutetium-177-Labeled (TANDEM) Somatostatin Receptor Antagonist DOTA-LM3 in Patients with Neuroendocrine Neoplasm: A Retrospective Study Concerning Safety and Survival. [PDF]

Cancers (Basel)
Perrone E, Calcagni ML, Leccisotti L, Moretti R, Ghai K, Eismant A, Parkar T, Greifenstein L, Baum RP.   +8 more
europepmc   +1 more source